Atila Biosystems built a 3x margin framework around measurable economics including 2x to 4x revenue per test, 30 percent lower reagent costs, 50 percent less manpower, and a 3x margin improvement.

At Atila BioSystems, we are dedicated to advancing clinical molecular diagnostics through the development of innovative nucleic acid amplification and detection technologies. Our mission is to make molecular testing faster, simpler, and more accessible without compromising accuracy. Our portfolio spans a wide range of diagnostic applications, including FDA EUA–approved COVID-19 testing, Non-Invasive Prenatal Testing (NIPT), HPV and STI detection, and Next-Generation Sequencing (NGS) cancer panels for lung, breast, colorectal, and other cancers. We offer over 40 extraction-free assays designed for respiratory infections, sexual health, urinary tract infections (UTIs), wound infections, and viral, bacterial, and fungal diseases. By eliminating the need for DNA or RNA extraction, Atila’s proprietary technologies streamline molecular workflows, reduce turnaround time, and maintain high analytical precision. Together with our global partners, we are expanding access to advanced molecular diagnostics and improving patient outcomes worldwide.